1. Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa.
- Author
-
Marin, D, Marktel, S, Bua, M, Szydlo, R M, Franceschino, A, Nathan, I, Foot, N, Crawley, C, Na Nakorn, T, Olavarria, E, Lennard, A, Neylon, A, O'Brien, S G, Goldman, J M, and Apperley, J F
- Subjects
- *
MYELOID leukemia , *IMATINIB , *PROGNOSIS - Abstract
We assessed clinical results in 145 patients with chronic myeloid leukaemia in chronic phase who satisfied criteria for interferon-a failure and were thus eligible for treatment with imatinib at the Hammersmith Hospital. We used univariate and multivariate analyses to develop a risk score based on features defined after treatment for 3 months. We identified a low neutrophil count and poor cytogenetic response (<35% Ph-negative marrow metaphases) at 3 months as principal independent predictive factors and incorporated them into a three-tier prognostic scoring system for individual patients. For patients in the low-, intermediate- and high-risk groups, the probabilities of survival at 24 months were 100, 82 and 40% (P<0.0001) and progression-free survival 100, 66 and 15% (P<0.0001), respectively. This Hammersmith prognostic scoring system was validated with an independent cohort of patients treated at another UK centre. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF